Innate Pharma SA (NAS:IPHA)

Half Year 2025 Innate Pharma SA Earnings Call Transcript

Sep 17, 2025 / 12:00PM GMT

Release Date Price: $2.05 (-1.44%)

Transcript

Key Points

Positve

Innate Pharma SA (IPHA) has made significant progress across its portfolio, focusing on three high-value clinical assets: IPH4502, lacutamab, and monalizumab.
IPH4502, a next-generation Nectin-4 ADC, shows potential to overcome resistance in urothelial cancer and expand into other tumor types with unmet medical needs.
Lacutamab has received FDA breakthrough therapy designation for Sezary syndrome, indicating potential for accelerated approval and a clear regulatory pathway.
Monalizumab, in partnership with AstraZeneca, is progressing in a Phase III trial, with significant milestone payments and potential royalties for Innate Pharma SA (IPHA).
The company has a strong cash position of EUR70.4 million, providing a runway until the end of the third quarter of 2026, supporting its strategic priorities.

Negative

Innate Pharma SA (IPHA) is undergoing organizational restructuring, which may involve headcount reductions, though specific financial impacts are not disclosed.
The strategic refocus means that NK cell programs are deprioritized, potentially limiting future innovation in this area.
The company faces challenges in securing partnerships or investor support to advance lacutamab into Phase III trials without financial constraints.
There is competition in the Nectin-4 ADC space, and differentiation of IPH4502 from existing therapies remains to be proven in clinical trials.
Operating expenses remain high, with EUR30.3 million reported for the first half of 2025, which could impact financial flexibility if revenue growth does not accelerate.

Operator

Thank you for standing by, and welcome to the Innate Pharma first half 2025 business update and financial results conference call. (Operator Instructions).

I'd now like to turn the call over to Stephanie Cornen, Vice President, Investor Relations and Communications. You may begin.

Stephanie Cornen

Innate Pharma SA - Vice President, Investor Relations, Communication and Commercial Strategy

Good morning and good afternoon, everyone. Thank you for joining us for Innate Pharma H1 2025 business update and financial results conference call. The press release and today's presentation are both available on the IR section of our website.

Before we begin, I'd like to remind everyone that today's presentation includes forward-looking statements based on current expectations. These statements involve risks and uncertainties that could cause actual results to differ materially.

I'll briefly cover today's agenda. Our CEO, Jonathan Dickinson, will discuss our strategic overview fast-forward and commercial opportunity. Our COO, YanNIS Morel, will

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.